IBXXF (Imagion Biosystems) Shares Outstanding (EOP): 487.54 Mil (As of Dec. 2025)


What is Imagion Biosystems Shares Outstanding (EOP)?

Imagion Biosystems IBXXF Shares Outstanding (EOP) is 487.54 Mil as of Dec. 2025. The stock has 4 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Imagion Biosystems's shares outstanding for the quarter that ended in Dec. 2025 was 487.54 Mil.

Imagion Biosystems's quarterly shares outstanding increased from Jun. 2025 (201.34 Mil) to Dec. 2025 (487.54 Mil). It means Imagion Biosystems issued new shares from Jun. 2025 to Dec. 2025 .

Imagion Biosystems's annual shares outstanding increased from Dec. 2024 (201.34 Mil) to Dec. 2025 (487.54 Mil). It means Imagion Biosystems issued new shares from Dec. 2024 to Dec. 2025 .


Imagion Biosystems  (OTCPK:IBXXF) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Imagion Biosystems Shares Outstanding (EOP) Related Terms


Imagion Biosystems Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Imagion Biosystems's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Imagion Biosystems Shares Outstanding (EOP) Chart

Imagion Biosystems Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only 28.03 28.03 32.65 201.34 487.54

Imagion Biosystems Semi-Annual Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.65 32.65 201.34 201.34 487.54

IBXXF vs TMO, DHR, IDXX: Shares Outstanding (EOP) Comparison

For the Diagnostics & Research subindustry, Imagion Biosystems's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Imagion Biosystems Shares Outstanding (EOP) vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Imagion Biosystems's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Imagion Biosystems's Shares Outstanding (EOP) falls into.



Imagion Biosystems Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 487.54 Mil mean?
Imagion Biosystems (IBXXF) has a Shares Outstanding (EOP) of 487.54 Mil as of Dec. 2025. The total shares a company has outstanding, at period-end. View historical data on Imagion Biosystems and its competitors.
Is Imagion Biosystems' Shares Outstanding (EOP) too high?
Imagion Biosystems' current Shares Outstanding (EOP) is 487.54 Mil.
How does Imagion Biosystems' Shares Outstanding (EOP) compare to TMO and DHR?
Imagion Biosystems' Shares Outstanding (EOP) of 487.54 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Medical Diagnostics & Research company?
A good Shares Outstanding (EOP) depends on the Medical Diagnostics & Research industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Imagion Biosystems and its competitors. Imagion Biosystems's current Shares Outstanding (EOP) is 487.54 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imagion Biosystems stock overvalued right now?
Based on GuruFocus' analysis, Imagion Biosystems (IBXXF) is currently considered Possible Value Trap. The stock's GF Value™ is $3.08, compared to a current price of $0.03 — trading 99% below its estimated fair value. The current Shares Outstanding (EOP) is 487.54 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Imagion Biosystems (IBXXF), the current Shares Outstanding (EOP) is 487.54 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Imagion Biosystems Business Description

Other Exchanges IBX:Australia
Address 385 Bourke Street, Suite 2, Level 11, Melbourne, VIC, AUS, 3000
Imagion Biosystems Ltd operates in the field of non-invasive detection of specific solid tumor cancers by use of magnetic nanoparticles. Its principal continuing activities consisted of Nanotechnology; Biotechnology; Cancer Diagnostics; and Medical Imaging using Magnetic Resonance and Superparamagnetic Relaxometry. The company only operating segment - Research and Development. Its principal business activities consist of nanotechnology, biotechnology, cancer diagnostics, and medical imaging using Superparamagnetic Relaxometry. In addition, the company is engaged in the research and development of its clinical phase lead product which is intended for the detection and staging of metastatic HER2 breast cancer. The company operates in Australia and the USA, with revenue from Australia.